N-acetylcysteine for the treatment of cannabis dependence: working mechanisms

Ki vehet részt

• Males, aged 18-45 years
• Current DSM-IV diagnosis of cannabis dependence
• >1 week detoxified and abstinent
• Able to provide written informed consent and to comply with study procedures
• Dutch speaking (Dutch as primary language)

Ki nem vehet részt

• Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants)
• History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease)
• An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches
• An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders
• Currently dependent on any substance other than cannabis, alcohol or nicotine
• Asthma